After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

COPENHAGEN (dpa-AFX) - Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, through a new partnership with WeightWatchers starting ...

Novo Nordisk has today forecast another year of double-digit record sales and operating profit growth as it began easing restrictions on supply of its popular weight-loss drug Wegovy.

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for a new and higher dose of its popular obesity medication, Wegovy ...